Angiosarcoma clinical trials at UCLA
1 in progress, 0 open to eligible people
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Sorry, in progress, not accepting new patients
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1 anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) human monoclonal antibody (botensilimab) monotherapy and in combination with an anti-programmed cell death protein-1 (PD-1) antibody (balstilimab), and to assess the maximum tolerated dose (MTD) in participants with advanced solid tumors. This study will also determine the recommended phase 2 dose (RP2D) of botensilimab monotherapy and in combination with balstilimab.
Los Angeles 5368361, California 5332921 and other locations
Our lead scientists for Angiosarcoma research studies include Jonathan Goldman, MD.
Last updated: